Halofuginone
- Generic Name
- Halofuginone
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17BrClN3O3
- CAS Number
- 55837-20-2
- Unique Ingredient Identifier
- L31MM1385E
- Background
Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice. Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000.
- Indication
For the treatment of scleroderma, cancer, and restenosis.
HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Akashi Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT02525302
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
Open Label Extension Study of HT-100 in Patients With DMD
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT01978366
- Locations
- 🇺🇸
Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT01847573
- Locations
- 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma
- Conditions
- Recurrent Kaposi SarcomaAIDS-related Kaposi Sarcoma
- Interventions
- Other: placeboOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00064142
- Locations
- 🇺🇸
AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States
Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-24
- Target Recruit Count
- 25
- Registration Number
- NCT00027677
- Locations
- 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇳🇱Daniel Den Hoed Cancer Center at Erasmus Medical Center, Rotterdam, Netherlands
🇳🇱University Hospital - Rotterdam Dijkzigt, Rotterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.